SAB BIOTHERAPEUTICS
A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
SAB BIOTHERAPEUTICS
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2014-06-01
Address:
Sioux Falls, South Dakota, United States
Country:
United States
Website Url:
http://www.sabbiotherapeutics.com
Total Employee:
51+
Status:
Active
Contact:
(605)679-6980
Total Funding:
40.42 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Microsoft Azure DNS GoDaddy DNS Google Google Cloud Gravity Forms AWS Global Accelerator
Similar Organizations
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Charles H. Randall CFO & Executive VP Support Services @ SAB Biotherapeutics
CFO & Executive VP Support Services
Eddie Sullivan President & CEO @ SAB Biotherapeutics
President & CEO
2014-06-01
Kipp Erickson COO @ SAB Biotherapeutics
COO
2021-03-01
Alexandra Kropotova Chief Medical Officer @ SAB Biotherapeutics
Chief Medical Officer
2022-01-01
Edward Hamilton Executive Chairman, Board of Directors @ SAB Biotherapeutics
Executive Chairman, Board of Directors
2014-07-01
Dr. Carlos Carrillo SVP Regulatory affairs @ SAB Biotherapeutics
SVP Regulatory affairs
2021-06-01
Samuel J. Reich Executive Chairman @ SAB Biotherapeutics
Executive Chairman
2021-10-01
Russell Beyer CFO @ SAB Biotherapeutics
CFO
2021-09-01
Founder
Stock Details
Investors List
South Dakota Equity Partners
South Dakota Equity Partners investment in Series B - SAB Biotherapeutics
Merck
Merck investment in Series B - SAB Biotherapeutics
South Dakota Equity Partners
South Dakota Equity Partners investment in Series A - SAB Biotherapeutics
National Institutes of Health
National Institutes of Health investment in Grant - SAB Biotherapeutics
Sioux Falls Development Foundation
Sioux Falls Development Foundation investment in Venture Round - SAB Biotherapeutics
Key Employee Changes
Official Site Inspections
http://www.sabbiotherapeutics.com
- Host name: 223.103.184.35.bc.googleusercontent.com
- IP address: 35.184.103.223
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "SAB Biotherapeutics"
Home - SAB BIO
Sep 13, 2024 The Constant Management of Type 1 Diabetes (T1D) Calls for Treatment Options that Address the Underlying Cause of Disease. The chronic burden of type 1 diabetes is …See details»
Company Profile - SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company working to treat and prevent immune and autoimmune disorders.See details»
SAB Biotherapeutics - Crunchbase Company Profile & Funding
SAB Biotherapeutics may be growing as evidenced by the company's recent financial activities and operational advancements. The company has announced the sale of $130 million shares …See details»
Our Science - SAB BIO
Our Science The SAB BIO Platform: A Novel Immunotherapy Platform For Developing Human Anti-Thymocyte Immunoglobulin . With our unique platform, SAB BIO is the only company in …See details»
SAB Biotherapeutics, Inc. (SABS) Company Profile & Overview
Nov 1, 2024 777 W 41st St., Suite 401 Miami Beach, Florida 33140 United StatesSee details»
SAB Biotherapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
SAB Biotherapeutics to List on Nasdaq through Merger with Big …
Jun 22, 2021 SAB Biotherapeutics (SAB) has entered into a definitive merger agreement with Big Cypress Acquisition Corp. (NASDAQ: BCYP) and upon closing, the combined company is …See details»
SAB Biotherapeutics Inc, SABS:NAQ profile - FT.com - Financial Times
Nov 22, 2024 SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the …See details»
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation ...
Oct 25, 2021 --SAB Biotherapeutics,, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human …See details»
SAB Biotherapeutics Debuts as Publicly Traded - GlobeNewswire
Oct 25, 2021 Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the...See details»
SAB Biotherapeutics Provides Company Update and Reports Full …
Mar 29, 2022 SAB Biotherapeutics, Inc. SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect …See details»
Our Pipeline - SAB BIO
Our Pipeline. SAB BIO continues to execute its corporate strategy through building partnerships and expertise that advances our focus on immunotherapy, specifically type 1 diabetes (T1D).See details»
SaBio Therapeutics - Home
At SaBio Therapeutics, we promote human health and wellness through better nutrition.See details»
SAB Biotherapeutics Announces Exclusive Manufacturing …
SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (“SAB”), a clinical-stage biopharmaceutical company with a …See details»
SaBio Therapeutics - Overview, News & Similar companies
SaBio Therapeutics contact info: Phone number: (786) 309-0910 Website: www.sabiotherapeutics.com What does SaBio Therapeutics do? We place high emphasis on …See details»
SAB Biotherapeutics Provides Company Update and Reports
Mar 29, 2022 SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patientsSee details»
Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19 October 4, 2021See details»
SAB Biotherapeutics advancing new class of ... - BioTuesdays
Sep 13, 2022 SAB Biotherapeutics (NASDAQ:SABS) is developing its novel DiversitAb platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal …See details»
SAB Biotherapeutics Announces Publication of Preclinical Data ...
July 8, 2021 SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 VariantsSee details»
News - SAB BIO
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19 October 4, 2021See details»